Cleared Traditional

K874895 - IR-192 IMPLANT

K874895 is an FDA 510(k) clearance for IR-192 IMPLANT, manufactured by Rads S.L., Inc.. The device is a Class 2 Radiology device with product code IWA cleared through the Traditional 510(k) pathway after a 86-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 1988
Decision
86d
Days
Class 2
Risk

K874895 is an FDA 510(k) clearance for the IR-192 IMPLANT. Classified as Source, Wire, Iridium, Radioactive (product code IWA), Class II - Special Controls.

Submitted by Rads S.L., Inc. (Lake Charles, US). The FDA issued a Cleared decision on February 25, 1988 after a review of 86 days - a notably fast clearance cycle.

This device falls under the Radiology FDA review panel, regulated under 21 CFR 892.5730 - the FDA radiology and imaging software oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Rads S.L., Inc. devices

FDA 510(k) Submission Details - K874895

510(k) Number K874895 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 01, 1987
Decision Date February 25, 1988
Days to Decision 86 days
Submission Type Traditional
Review Panel Radiology (RA)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
21d faster than avg
Panel avg: 107d · This submission: 86d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

IWA Device Classification - Class 2, Special Controls

Product Code IWA Source, Wire, Iridium, Radioactive
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 892.5730
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Radiology devices follow this clearance model.